{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T23:39:32Z","timestamp":1794613172683,"version":"4.9.1"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T00:00:00Z","timestamp":1769040000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T00:00:00Z","timestamp":1769040000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sig Transduct Target Ther"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Conversion therapy remains an uncommon strategy for managing unresectable hepatocellular carcinoma (uHCC) due to limited evidence supporting its efficacy. To address this gap, we initiated a prospective phase 2 multicenter trial (NCT04997850) comparing the LEN-TAP regimen, combining lenvatinib, transarterial chemoembolization (TACE), and PD-1 inhibitors, against TACE alone in uHCC patients. The study\u2019s primary outcome was salvage liver resection (SLR) rate; secondary measures included objective response rate (ORR), overall survival (OS), event-free survival (EFS), recurrence-free survival (RFS), and safety profile. From October 2020 to November 2021, 142 eligible participants were assigned to LEN-TAP (n\u2009=\u200971) or TACE monotherapy (n\u2009=\u200971). At a median follow-up of 24.2 months, the LEN-TAP cohort exhibited a significantly higher SLR rate (59.2% vs. 18.3%, P\u2009&lt;\u20090.001) and ORR (78.9% vs. 16.9%, P\u2009&lt;\u20090.001). Median OS, EFS, and RFS were also substantially prolonged in the LEN-TAP cohort (not reached vs. 23.0 months, P\u2009&lt;\u20090.001; 20.03 vs. 6.52 months, P\u2009&lt;\u20090.001; 36.6 vs. 19.0 months, P\u2009=\u20090.048). Although grade 3 treatment-related AEs occurred more frequently with LEN-TAP (60.6% vs. 21.1%, P\u2009&lt;\u20090.001), no grade 4 or higher toxicities were observed. Exploratory biomarker assessments via single-cell sequencing and flow cytometry linked elevated levels of circulating HLA-DR\n                    <jats:sup>+<\/jats:sup>\n                    CD38\n                    <jats:sup>+<\/jats:sup>\n                    CD8\n                    <jats:sup>+<\/jats:sup>\n                    T cells with improved treatment response. These T cells appear to mediate antitumor activity potentially through the CXCR6\u2013PI3K\u2013AKT signaling axis. In summary, the LEN-TAP protocol demonstrates promising efficacy and acceptable tolerability as a conversion therapy in uHCC, with peripheral HLA-DR\n                    <jats:sup>+<\/jats:sup>\n                    CD38\n                    <jats:sup>+<\/jats:sup>\n                    CD8\n                    <jats:sup>+<\/jats:sup>\n                    T cell abundance serving as a potential predictor of therapeutic benefit.\n                  <\/jats:p>","DOI":"10.1038\/s41392-025-02498-z","type":"journal-article","created":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T00:02:25Z","timestamp":1769040145000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Lenvatinib plus transarterial chemoembolization and PD-1 inhibitors as conversion therapies for unresectable intermediate-advanced hepatocellular carcinoma: a phase 2 trial and exploratory biomolecular study"],"prefix":"10.1038","volume":"11","author":[{"given":"Xiaoyun","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haozheng","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiqing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"JiaYi","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinrui","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weixin","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongjie","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junyi","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaozhong","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weixia","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0494-6023","authenticated-orcid":false,"given":"Yujun","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wusheng","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6554-7088","authenticated-orcid":false,"given":"Xin","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xielin","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9852-2661","authenticated-orcid":false,"given":"Maolin","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6760-7470","authenticated-orcid":false,"given":"Shuqun","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianfu","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,22]]},"reference":[{"key":"2498_CR1","first-page":"209","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung, H. et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 71, 209\u2013249 (2021).","journal-title":"CA Cancer J. Clin."},{"key":"2498_CR2","doi-asserted-by":"publisher","first-page":"2155","DOI":"10.1111\/liv.12818","volume":"35","author":"JW Park","year":"2015","unstructured":"Park, J. W. et al. Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE Study. Liver Int. 35, 2155\u20132166 (2015).","journal-title":"Liver Int."},{"key":"2498_CR3","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1002\/hep.29883","volume":"68","author":"MH Hyun","year":"2018","unstructured":"Hyun, M. H. et al. Hepatic resection compared to chemoembolization in intermediate- to advanced-stage hepatocellular carcinoma: a meta-analysis of high-quality studies. Hepatology 68, 977\u2013993 (2018).","journal-title":"Hepatology"},{"key":"2498_CR4","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1097\/SLA.0000000000000236","volume":"260","author":"JH Zhong","year":"2014","unstructured":"Zhong, J. H. et al. Hepatic resection associated with good survival for selected patients with intermediate and advanced-stage hepatocellular carcinoma. Ann. Surg. 260, 329\u2013340 (2014).","journal-title":"Ann. Surg."},{"key":"2498_CR5","doi-asserted-by":"publisher","first-page":"227","DOI":"10.21037\/hbsn-21-328","volume":"11","author":"HC Sun","year":"2022","unstructured":"Sun, H. C. et al. Chinese expert consensus on conversion therapy for hepatocellular carcinoma (2021 edition). Hepatobiliary Surg. Nutr. 11, 227\u2013252 (2022).","journal-title":"Hepatobiliary Surg. Nutr."},{"key":"2498_CR6","doi-asserted-by":"publisher","first-page":"130","DOI":"10.5582\/bst.2022.01019","volume":"16","author":"H Tang","year":"2022","unstructured":"Tang, H. et al. Conversion therapy with an immune checkpoint inhibitor and an antiangiogenic drug for advanced hepatocellular carcinoma: a review. Biosci. Trends 16, 130\u2013141 (2022).","journal-title":"Biosci. Trends"},{"key":"2498_CR7","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1111\/j.1572-0241.2007.01712.x","volume":"103","author":"A Sergio","year":"2008","unstructured":"Sergio, A. et al. Transcatheter arterial chemoembolization (TACE) in hepatocellular carcinoma (HCC): the role of angiogenesis and invasiveness. Am. J. Gastroenterol. 103, 914\u2013921 (2008).","journal-title":"Am. J. Gastroenterol."},{"key":"2498_CR8","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1159\/000502905","volume":"8","author":"M Kudo","year":"2019","unstructured":"Kudo, M. A new treatment option for intermediate-stage hepatocellular carcinoma with high tumor burden: initial lenvatinib therapy with subsequent selective TACE. Liver Cancer 8, 299\u2013311 (2019).","journal-title":"Liver Cancer"},{"key":"2498_CR9","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1200\/JCO.22.00392","volume":"41","author":"Z Peng","year":"2023","unstructured":"Peng, Z. et al. Lenvatinib combined with transarterial chemoembolization as first-line treatment for advanced hepatocellular carcinoma: a phase III, randomized clinical trial (LAUNCH). J. Clin. Oncol. 41, 117\u2013127 (2023).","journal-title":"J. Clin. Oncol."},{"key":"2498_CR10","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1016\/j.jhep.2019.01.027","volume":"70","author":"TF Greten","year":"2019","unstructured":"Greten, T. F. et al. Combined locoregional-immunotherapy for liver cancer. J. Hepatol. 70, 999\u20131007 (2019).","journal-title":"J. Hepatol."},{"key":"2498_CR11","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1159\/000494843","volume":"8","author":"MS Dendy","year":"2019","unstructured":"Dendy, M. S., Ludwig, J. M., Stein, S. M. & Kim, H. S. Locoregional therapy, immunotherapy and the combination in hepatocellular carcinoma: future directions. Liver Cancer 8, 326\u2013340 (2019).","journal-title":"Liver Cancer"},{"key":"2498_CR12","doi-asserted-by":"publisher","first-page":"zrac114","DOI":"10.1093\/bjsopen\/zrac114","volume":"6","author":"WF Qu","year":"2022","unstructured":"Qu, W. F. et al. Conversion therapy for initially unresectable hepatocellular carcinoma using a combination of toripalimab, lenvatinib plus TACE: real-world study. BJS Open. 6, zrac114 (2022).","journal-title":"BJS Open."},{"key":"2498_CR13","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.2147\/JHC.S332420","volume":"8","author":"JY Wu","year":"2021","unstructured":"Wu, J. Y. et al. Lenvatinib combined with anti-PD-1 antibodies plus transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma: a multicenter retrospective study. J. Hepatocell. Carcinoma 8, 1233\u20131240 (2021).","journal-title":"J. Hepatocell. Carcinoma"},{"key":"2498_CR14","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1038\/s41392-022-01235-0","volume":"8","author":"HD Zhu","year":"2023","unstructured":"Zhu, H. D. et al. Transarterial chemoembolization with PD-(L)1 inhibitors plus molecular targeted therapies for hepatocellular carcinoma (CHANCE001). Signal Transduct. Target Ther. 8, 58 (2023).","journal-title":"Signal Transduct. Target Ther."},{"key":"2498_CR15","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1158\/2326-6066.CIR-19-0398","volume":"8","author":"J Han","year":"2020","unstructured":"Han, J. et al. TCR repertoire diversity of peripheral PD-1(+)CD8(+) T cells predicts clinical outcomes after immunotherapy in patients with non-small cell lung cancer. Cancer Immunol. Res. 8, 146\u2013154 (2020).","journal-title":"Cancer Immunol. Res."},{"key":"2498_CR16","doi-asserted-by":"publisher","first-page":"4993","DOI":"10.1073\/pnas.1705327114","volume":"114","author":"AO Kamphorst","year":"2017","unstructured":"Kamphorst, A. O. et al. Proliferation of PD-1+ CD8 T cells in peripheral blood after PD-1-targeted therapy in lung cancer patients. Proc. Natl. Acad. Sci. USA 114, 4993\u20134998 (2017).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2498_CR17","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1038\/s41591-019-0357-y","volume":"25","author":"AC Huang","year":"2019","unstructured":"Huang, A. C. et al. A single dose of neoadjuvant PD-1 blockade predicts clinical outcomes in resectable melanoma. Nat. Med 25, 454\u2013461 (2019).","journal-title":"Nat. Med"},{"key":"2498_CR18","unstructured":"Carlisle, J. W. et al. Clinical outcome following checkpoint therapy in renal cell carcinoma is associated with a burst of activated CD8 T cells in blood. J. Immunother Cancer. 10, (2022)."},{"key":"2498_CR19","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/978-981-15-3266-5_3","volume":"1248","author":"L Ai","year":"2020","unstructured":"Ai, L., Xu, A. & Xu, J. Roles of PD-1\/PD-L1 pathway: signaling, cancer, and beyond. Adv. Exp. Med. Biol. 1248, 33\u201359 (2020).","journal-title":"Adv. Exp. Med. Biol."},{"key":"2498_CR20","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1002\/hep.32740","volume":"77","author":"R Donne","year":"2023","unstructured":"Donne, R. & Lujambio, A. The liver cancer immune microenvironment: therapeutic implications for hepatocellular carcinoma. Hepatology 77, 1773\u20131796 (2023).","journal-title":"Hepatology"},{"key":"2498_CR21","doi-asserted-by":"publisher","first-page":"3099","DOI":"10.4049\/jimmunol.181.5.3099","volume":"181","author":"S Matsumura","year":"2008","unstructured":"Matsumura, S. et al. Radiation-induced CXCL16 release by breast cancer cells attracts effector T cells. J. Immunol. 181, 3099\u20133107 (2008).","journal-title":"J. Immunol."},{"key":"2498_CR22","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1111\/j.1365-2249.2008.03745.x","volume":"154","author":"MM Gaida","year":"2008","unstructured":"Gaida, M. M. et al. Expression of the CXCR6 on polymorphonuclear neutrophils in pancreatic carcinoma and in acute, localized bacterial infections. Clin. Exp. Immunol. 154, 216\u2013223 (2008).","journal-title":"Clin. Exp. Immunol."},{"key":"2498_CR23","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/S2468-1253(22)00339-9","volume":"8","author":"CL Chiang","year":"2023","unstructured":"Chiang, C. L. et al. Sequential transarterial chemoembolisation and stereotactic body radiotherapy followed by immunotherapy as conversion therapy for patients with locally advanced, unresectable hepatocellular carcinoma (START-FIT): a single-arm, phase 2 trial. Lancet Gastroenterol. Hepatol. 8, 169\u2013178 (2023).","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"2498_CR24","doi-asserted-by":"publisher","first-page":"2960","DOI":"10.1200\/JCO.20.00808","volume":"38","author":"RS Finn","year":"2020","unstructured":"Finn, R. S. et al. Phase Ib study of lenvatinib plus pembrolizumab in patients with unresectable hepatocellular carcinoma. J. Clin. Oncol. 38, 2960\u20132970 (2020).","journal-title":"J. Clin. Oncol."},{"key":"2498_CR25","doi-asserted-by":"publisher","first-page":"3993","DOI":"10.1111\/cas.13806","volume":"109","author":"T Kimura","year":"2018","unstructured":"Kimura, T. et al. Immunomodulatory activity of lenvatinib contributes to antitumor activity in the Hepa1-6 hepatocellular carcinoma model. Cancer Sci. 109, 3993\u20134002 (2018).","journal-title":"Cancer Sci."},{"key":"2498_CR26","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/j.jhep.2021.11.018","volume":"76","author":"M Reig","year":"2022","unstructured":"Reig, M. et al. BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update. J. Hepatol. 76, 681\u2013693 (2022).","journal-title":"J. Hepatol."},{"key":"2498_CR27","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1148\/radiol.10101058","volume":"258","author":"GE Chung","year":"2011","unstructured":"Chung, G. E. et al. Transarterial chemoembolization can be safely performed in patients with hepatocellular carcinoma invading the main portal vein and may improve the overall survival. Radiology 258, 627\u2013634 (2011).","journal-title":"Radiology"},{"key":"2498_CR28","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1016\/j.ejso.2019.03.042","volume":"45","author":"X Xiang","year":"2019","unstructured":"Xiang, X. et al. Transarterial chemoembolization versus best supportive care for patients with hepatocellular carcinoma with portal vein tumor thrombus: a multicenter study. Eur. J. Surg. Oncol. 45, 1460\u20131467 (2019).","journal-title":"Eur. J. Surg. Oncol."},{"key":"2498_CR29","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1245\/s10434-010-1321-8","volume":"18","author":"J Luo","year":"2011","unstructured":"Luo, J. et al. Transarterial chemoembolization for unresectable hepatocellular carcinoma with portal vein tumor thrombosis: a prospective comparative study. Ann. Surg. Oncol. 18, 413\u2013420 (2011).","journal-title":"Ann. Surg. Oncol."},{"key":"2498_CR30","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1159\/000509424","volume":"9","author":"J Zhou","year":"2020","unstructured":"Zhou, J. et al. Guidelines for the diagnosis and treatment of hepatocellular carcinoma (2019 Edition). Liver Cancer 9, 682\u2013720 (2020).","journal-title":"Liver Cancer"},{"key":"2498_CR31","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1159\/000514174","volume":"10","author":"M Kudo","year":"2021","unstructured":"Kudo, M. et al. Management of hepatocellular carcinoma in Japan: JSH consensus statements and recommendations 2021 update. Liver Cancer 10, 181\u2013223 (2021).","journal-title":"Liver Cancer"},{"key":"2498_CR32","doi-asserted-by":"crossref","unstructured":"2018 Korean Liver Cancer Association-National Cancer Center Korea Practice Guidelines for the Management of Hepatocellular Carcinoma. Gut Liver. 13, 227\u2013299 (2019).","DOI":"10.5009\/gnl19024"},{"key":"2498_CR33","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1097\/SLA.0b013e31821ad884","volume":"254","author":"KC Lim","year":"2011","unstructured":"Lim, K. C. et al. Microvascular invasion is a better predictor of tumor recurrence and overall survival following surgical resection for hepatocellular carcinoma compared to the Milan criteria. Ann. Surg. 254, 108\u2013113 (2011).","journal-title":"Ann. Surg."},{"key":"2498_CR34","doi-asserted-by":"publisher","first-page":"7101","DOI":"10.7314\/APJCP.2013.14.12.7101","volume":"14","author":"WJ Zhu","year":"2013","unstructured":"Zhu, W. J. et al. Risk factors for early recurrence of HBV-related hepatocellular carcinoma meeting milan criteria after curative resection. Asian Pac. J. Cancer Prev. 14, 7101\u20137106 (2013).","journal-title":"Asian Pac. J. Cancer Prev."},{"key":"2498_CR35","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1245\/s10434-012-2513-1","volume":"20","author":"M Rodr\u00edguez-Per\u00e1lvarez","year":"2013","unstructured":"Rodr\u00edguez-Per\u00e1lvarez, M. et al. A systematic review of microvascular invasion in hepatocellular carcinoma: diagnostic and prognostic variability. Ann. Surg. Oncol. 20, 325\u2013339 (2013).","journal-title":"Ann. Surg. Oncol."},{"key":"2498_CR36","first-page":"495","volume":"3","author":"ZY Tang","year":"2004","unstructured":"Tang, Z. Y. et al. Downstaging followed by resection plays a role in improving prognosis of unresectable hepatocellular carcinoma. Hepatobiliary Pancreat. Dis. Int. 3, 495\u2013498 (2004).","journal-title":"Hepatobiliary Pancreat. Dis. Int."},{"key":"2498_CR37","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1159\/000514313","volume":"10","author":"XD Zhu","year":"2021","unstructured":"Zhu, X. D. et al. Downstaging and resection of initially unresectable hepatocellular carcinoma with tyrosine kinase inhibitor and anti-PD-1 antibody combinations. Liver Cancer 10, 320\u2013329 (2021).","journal-title":"Liver Cancer"},{"key":"2498_CR38","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.735125","volume":"12","author":"J Du","year":"2021","unstructured":"Du, J. et al. Persistent high percentage of HLA-DR(+)CD38(high) CD8(+) T cells associated with immune disorder and disease severity of COVID-19. Front Immunol. 12, 735125 (2021).","journal-title":"Front Immunol."},{"key":"2498_CR39","doi-asserted-by":"publisher","first-page":"1782","DOI":"10.1002\/jmv.24852","volume":"89","author":"L Lins","year":"2017","unstructured":"Lins, L. et al. Increased expression of CD38 and HLADR in HIV-infected patients with oral lesion. J. Med Virol. 89, 1782\u20131787 (2017).","journal-title":"J. Med Virol."},{"key":"2498_CR40","doi-asserted-by":"publisher","first-page":"e31535","DOI":"10.1371\/journal.pone.0031535","volume":"7","author":"A Fox","year":"2012","unstructured":"Fox, A. et al. Severe pandemic H1N1 2009 infection is associated with transient NK and T deficiency and aberrant CD8 responses. PLoS One 7, e31535 (2012).","journal-title":"PLoS One"},{"key":"2498_CR41","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1038\/ni.2035","volume":"12","author":"EJ Wherry","year":"2011","unstructured":"Wherry, E. J. T cell exhaustion. Nat. Immunol. 12, 492\u2013499 (2011).","journal-title":"Nat. Immunol."},{"key":"2498_CR42","doi-asserted-by":"publisher","first-page":"1022136","DOI":"10.3389\/fimmu.2022.1022136","volume":"13","author":"N Mabrouk","year":"2022","unstructured":"Mabrouk, N. et al. CXCR6 expressing T cells: functions and role in the control of tumors. Front Immunol. 13, 1022136 (2022).","journal-title":"Front Immunol."},{"key":"2498_CR43","doi-asserted-by":"publisher","first-page":"3546","DOI":"10.1158\/0008-5472.CAN-11-4032","volume":"72","author":"Q Gao","year":"2012","unstructured":"Gao, Q. et al. CXCR6 upregulation contributes to a proinflammatory tumor microenvironment that drives metastasis and poor patient outcomes in hepatocellular carcinoma. Cancer Res. 72, 3546\u20133556 (2012).","journal-title":"Cancer Res."},{"key":"2498_CR44","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2019.126899","volume":"30","author":"S Peddibhotla","year":"2020","unstructured":"Peddibhotla, S. et al. Discovery of small molecule antagonists of chemokine receptor CXCR6 that arrest tumor growth in SK-HEP-1 mouse xenografts as a model of hepatocellular carcinoma. Bioorg. Med. Chem. Lett. 30, 126899 (2020).","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"2498_CR45","doi-asserted-by":"publisher","first-page":"4512","DOI":"10.1016\/j.cell.2021.07.015","volume":"184","author":"M Di Pilato","year":"2021","unstructured":"Di Pilato, M. et al. CXCR6 positions cytotoxic T cells to receive critical survival signals in the tumor microenvironment. Cell 184, 4512\u20134530.e4522 (2021).","journal-title":"Cell"},{"key":"2498_CR46","doi-asserted-by":"publisher","first-page":"1877","DOI":"10.1053\/j.gastro.2019.01.247","volume":"156","author":"JC Mossanen","year":"2019","unstructured":"Mossanen, J. C. et al. CXCR6 inhibits hepatocarcinogenesis by promoting natural killer T- and CD4(+) T-cell-dependent control of senescence. Gastroenterology 156, 1877\u20131889.e1874 (2019).","journal-title":"Gastroenterology"},{"key":"2498_CR47","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1016\/j.intimp.2019.04.021","volume":"72","author":"H Zhu","year":"2019","unstructured":"Zhu, H., Zhang, Q. & Chen, G. CXCR6 deficiency ameliorates ischemia-reperfusion injury by reducing the recruitment and cytokine production of hepatic NKT cells in a mouse model of non-alcoholic fatty liver disease. Int. Immunopharmacol. 72, 224\u2013234 (2019).","journal-title":"Int. Immunopharmacol."},{"key":"2498_CR48","doi-asserted-by":"publisher","first-page":"e113","DOI":"10.1371\/journal.pbio.0030113","volume":"3","author":"F Geissmann","year":"2005","unstructured":"Geissmann, F. et al. Intravascular immune surveillance by CXCR6+ NKT cells patrolling liver sinusoids. PLoS Biol. 3, e113 (2005).","journal-title":"PLoS Biol."},{"key":"2498_CR49","doi-asserted-by":"crossref","unstructured":"Ma, C. et al. Gut microbiome-mediated bile acid metabolism regulates liver cancer via NKT cells. Science 360, (2018).","DOI":"10.1126\/science.aan5931"},{"key":"2498_CR50","first-page":"217","volume":"436","author":"P Gaur","year":"2022","unstructured":"Gaur, P. et al. PI3K isoforms in CD8(+) T cell development and function. Curr. Top. Microbiol. Immunol. 436, 217\u2013234 (2022).","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"2498_CR51","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2024.113529","volume":"143","author":"Z Liu","year":"2024","unstructured":"Liu, Z. et al. Silencing CXCR6 promotes epithelial-mesenchymal transition and invasion in colorectal cancer by activating the VEGFA\/PI3K\/AKT\/mTOR pathway. Int. Immunopharmacol. 143, 113529 (2024).","journal-title":"Int. Immunopharmacol."},{"key":"2498_CR52","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1530\/REP-18-0417","volume":"157","author":"J Mei","year":"2019","unstructured":"Mei, J. et al. CXCL16\/CXCR6 interaction promotes endometrial decidualization via the PI3K\/AKT pathway. Reproduction 157, 273\u2013282 (2019).","journal-title":"Reproduction"},{"key":"2498_CR53","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1053\/jhep.2002.33156","volume":"35","author":"CM Lo","year":"2002","unstructured":"Lo, C. M. et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 35, 1164\u20131171 (2002).","journal-title":"Hepatology"},{"key":"2498_CR54","doi-asserted-by":"publisher","first-page":"1734","DOI":"10.1016\/S0140-6736(02)08649-X","volume":"359","author":"JM Llovet","year":"2002","unstructured":"Llovet, J. M. et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 359, 1734\u20131739 (2002).","journal-title":"Lancet"},{"key":"2498_CR55","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1148\/radiol.12111550","volume":"263","author":"M Pinter","year":"2012","unstructured":"Pinter, M. et al. Advanced-stage hepatocellular carcinoma: transarterial chemoembolization versus sorafenib. Radiology 263, 590\u2013599 (2012).","journal-title":"Radiology"},{"key":"2498_CR56","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1016\/S1470-2045(21)00252-7","volume":"22","author":"Z Ren","year":"2021","unstructured":"Ren, Z. et al. Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2-3 study. Lancet Oncol. 22, 977\u2013990 (2021).","journal-title":"Lancet Oncol."},{"key":"2498_CR57","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1016\/S1470-2045(20)30011-5","volume":"21","author":"S Qin","year":"2020","unstructured":"Qin, S. et al. Camrelizumab in patients with previously treated advanced hepatocellular carcinoma: a multicentre, open-label, parallel-group, randomised, phase 2 trial. Lancet Oncol. 21, 571\u2013580 (2020).","journal-title":"Lancet Oncol."},{"key":"2498_CR58","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1148\/radiol.14131946","volume":"272","author":"K Zhu","year":"2014","unstructured":"Zhu, K. et al. Hepatocellular carcinoma with portal vein tumor thrombus: treatment with transarterial chemoembolization combined with sorafenib-a retrospective controlled study. Radiology 272, 284\u2013293 (2014).","journal-title":"Radiology"},{"key":"2498_CR59","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.jhep.2015.01.023","volume":"63","author":"MA Allard","year":"2015","unstructured":"Allard, M. A. et al. Does pathological response after transarterial chemoembolization for hepatocellular carcinoma in cirrhotic patients with cirrhosis predict outcome after liver resection or transplantation?. J. Hepatol. 63, 83\u201392 (2015).","journal-title":"J. Hepatol."}],"container-title":["Signal Transduction and Targeted Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41392-025-02498-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-025-02498-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-025-02498-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T00:02:28Z","timestamp":1769040148000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41392-025-02498-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,22]]},"references-count":59,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2498"],"URL":"https:\/\/doi.org\/10.1038\/s41392-025-02498-z","relation":{},"ISSN":["2059-3635"],"issn-type":[{"value":"2059-3635","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,22]]},"assertion":[{"value":"3 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 July 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 November 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 January 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"37"}}